BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment

Condition(s) studied

Investigational drug(s) / intervention(s)

Weight loss without pharmacotherapy: The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.

Study summary

1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments.
2. To establish the BMI at which this disease occurs.
3. To establish how much the BMI must be reduced to cure this disease.
4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion

Eligibility

Primary outcome measure(s)

• Response to treatment — Through study completion, an average of 1 year
  BMI evolution in patients with benign intracranial hypertension and its relationship with the evolution of the patient's symptoms

Trial sites (1)

More University of Valencia trials in Spain